Related references
Note: Only part of the references are listed.Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
Corey J. Langer et al.
CANCER TREATMENT REVIEWS (2013)
Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer
Perri Rozenberg et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers et al.
CLINICAL CANCER RESEARCH (2012)
Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors
Swee Y. Sharp et al.
PLOS ONE (2012)
Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy
W-J Lu et al.
CELL DEATH AND DIFFERENTIATION (2011)
Tanespimycin as Antitumor Therapy
Meletios-Athanassios Dimopoulos et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin
Wen-Jing Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A Compound That Inhibits the HOP-Hsp90 Complex Formation and Has Unique Killing Effects in Breast Cancer Cell Lines
Genaro Pimienta et al.
MOLECULAR PHARMACEUTICS (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Hepatocellular Carcinoma (HCC) A Global Perspective
Peter Ferenci et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2010)
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms
Min Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The p53 orchestra: Mdm2 and Mdmx set the tone
Mark Wade et al.
TRENDS IN CELL BIOLOGY (2010)
Targeting Heat Shock Protein 90 with Non-Quinone Inhibitors: A Novel Chemotherapeutic Approach in Human Hepatocellular Carcinoma
Marco Breinig et al.
HEPATOLOGY (2009)
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
E. Drakos et al.
LEUKEMIA (2009)
Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma
Olivier Ayrault et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Glucose-regulated protein 75 suppresses apoptosis induced by glucose deprivation in PC12 cells through inhibition of Bax conformational change
Ling Yang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2008)
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis
Marissa V. Powers et al.
CANCER CELL (2008)
Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence
Xin Yi et al.
MOLECULAR & CELLULAR PROTEOMICS (2008)
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth
Sven A. Lang et al.
CLINICAL CANCER RESEARCH (2007)
Mortalin sensitizes human cancer cells to MKT-077-induced senescence
Custer C. Deocaris et al.
CANCER LETTERS (2007)
Soothing the watchman - Telomerase reduces the p53-dependent cellular stress response
Alain Beliveau et al.
CELL CYCLE (2007)
TP53 mutations and hepatocellular carcinoma:: insights into the etiology and pathogenesis of liver cancer
S. P. Hussain et al.
ONCOGENE (2007)
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin
Alison Maloney et al.
CANCER RESEARCH (2007)
Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis
Rena Wadhwa et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues
Lata T. Gooljarsingh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Altered protein profile in Chronic Myelold Leukemia chronic phase identified by a comparative proteomic study
Luciana Pizzatti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2006)
Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides
SC Kaul et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Heat shock proteins as emerging therapeutic targets
C Soti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Targeting apoptosis pathways in cancer therapy
IM Ghobrial et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells
R Wadhwa et al.
JOURNAL OF GENE MEDICINE (2004)
Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein
R Wadhwa et al.
EXPERIMENTAL CELL RESEARCH (2002)
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
An N-terminal region of mot-2 binds to p53 in vitro
SC Kaul et al.
NEOPLASIA (2001)
Share Paper
